{"prompt": "['Gal\u00e1pagos', 'CLINICAL STUDY PROTOCOL (CSP)', 'Project Number:', 'GLPG1690', 'Study Number:', 'GLPG1690-CL-204', 'Study Title:', 'A Phase 2a randomized, double-blind, placebo-controlled, multi-', 'center study to evaluate the efficacy, safety, and tolerability of', 'orally administered GLPG1690 for 24 weeks in subjects with', 'systemic sclerosis', 'Development Phase:', '2a', 'Status:', 'Final', 'CSP Version:', '5.00', 'Date:', '28-Apr-2020', 'Amendment:', '3', 'EudraCT No.:', '2018-001817-33', 'CT.gov No.:', 'NCT03798366', 'IND No.:', '140691', 'Sponsor:', 'Galapagos NV, Generaal De Wittelaan L11 A3, 2800 Mechelen,', 'Belgium', 'Study Physician:', 'MD', 'General Protocol', 'CONFIDENTIALITY STATEMENT', 'The information contained in this document is privileged and confidential. It is the property of Galapagos NV and may not be', 'used, disclosed, reproduced or otherwise disseminated within your organization or communicated to any third parties without', 'the express written authorization of Galapagos NV.']['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 2/80', 'EMERGENCY CONTACT INFORMATION', 'In case of a serious adverse event (SAE), a Special Situation (see Section 9.1.6), or in case', 'of pregnancy during the clinical study, the investigator must report this immediately, and under', 'no circumstances later than 24 hours following the knowledge of the SAE or pregnancy, as', 'follows:', 'Fax #:', 'or', 'E-mail:', 'In case of medical questions during the course of the study, the investigator must contact the', 'contract research organization (CRO) Medical Monitor. For urgent medical/safety questions,', 'the investigator can contact the safety hotline.', 'CRO Lead Medical Monitor:', 'Contact Safety Hotline:', 'EMEA:', 'North America:', 'Sponsor Contact Number:', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']['Clinical Study Protocol (CSP) GLPG1690-CL-204', 'Page 3/80', 'TABLE OF CONTENTS', 'Emergency Contact Information', '2', 'Table of Contents', '3', 'Clinical Study Protocol History', '7', 'Summary of Changes', '8', 'List of Abbreviations and Definition of Terms', '13', '1. Summary', '17', '2. Introduction', '19', '2.1. Background - Nonclinical Studies', '20', '2.1.1. Physical, Chemical, Pharmaceutical Properties, and Formulation', '20', '2.1.2. Pharmacology', '20', '2.1.2.1. Primary and Secondary Pharmacology', '20', '2.1.2.2. Safety Pharmacology', '21', '2.1.3. Nonclinical Pharmacokinetics and Product Metabolism', '21', '2.1.4. Toxicology', '22', '2.1.4.1. General Toxicology', '22', '2.2. Background - Clinical Studies', '23', '2.2.1. Clinical Safety', '23', '2.2.2. Clinical Efficacy', '23', '2.2.3. Clinical Pharmacokinetics', '24', '2.2.4. Clinical Pharmacodynamics', '24', '3. Clinical Study Objectives', '25', '3.1. Primary Objective', '25', '3.2. Secondary Objective', '25', '3.3. Other Objectives', '25', '4. Investigational Plan', '25', '4.1. Overall Clinical Study Design', '25', '4.2. Clinical Study Rationale', '27', '4.2.1. Dose Rationale', '28', '4.2.2. Clinical Study Design Rationale', '28', '4.3. Endpoints', '28', '4.3.1. Primary Endpoint', '29', '4.3.2. Secondary Endpoint', '29', '4.3.3.Other Endpoints', '29', '4.4. Potential Risks and Benefits', '29', '4.5. Clinical Study Population', '31', '4.5.1. Inclusion Criteria', '31', '4.5.2. Exclusion Criteria', '32', '4.5.3. Prohibition and Restrictions', '33', '4.5.3.1. Precautions for Sexual Intercourse', '33', '4.5.3.2. Prior and Concomitant Medications', '35', '4.5.3.3. Food and Beverage Restrictions', '38', '4.5.3.4. Other Prohibitions and Restrictions', '38', '4.5.4. Treatment Discontinuation (Temporarily and Permanently), Subject', 'Withdrawal, and Study Termination', '38', '4.6. Measures to Minimize Bias', '40', '4.6.1. Randomization', '40', 'Version 5.00, Final, 28-Apr-2020', 'Confidential Information']\n\n###\n\n", "completion": "END"}